CMTM Family and Gastrointestinal Tract Cancers: A Comprehensive Review

Jie Li¹, Xiaozi Wang², Xiaoning Wang¹, Yan Liu¹, Na Zheng¹, Pengwei Xu², Xianghong Zhang², Liying Xue²

¹Department of Hematology, Hebei General Hospital, Shijiazhuang, 050000, People's Republic of China; ²Laboratory of Pathology, Hebei Medical University, Shijiazhuang, 050000, People's Republic of China

Correspondence: Liying Xue, Laboratory of Pathology, Hebei Medical University, No. 361, Zhongshan Eastern Road, Shijiazhuang, 050000, People's Republic of China, Tel +86 311 86265561, Email xueliying123@163.com

Abstract: Gastrointestinal tract cancers are a highly heterogeneous group of malignant diseases, contributing significantly to the burden of death worldwide. Chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing family (CMTMs) plays important roles in cancer development and progression. Since the first member was cloned, there have been abundant studies on the relationships between the CMTM family and human cancers. It has been reported that the CMTM family has a large potential prognostic value for multiple cancers. Meanwhile, upregulated or downregulated expression of the family members was related to advanced tumor stage, metastasis, and overall survival. Studies have also reported that these proteins play critical roles in antitumor immunity. We performed a systematic review to sum up the latest advances of CMTM family roles in gastrointestinal tract cancers, with a primary focus on hepatocellular carcinoma and gastric carcinoma.

Keywords: CMTM family, gastrointestinal tract cancers, MARVEL, hepatocellular carcinoma, gastric carcinoma

Introduction

Gastrointestinal tract cancers are a highly heterogeneous group of malignant diseases, including esophageal carcinoma (EC), gastric carcinoma (GC), colorectal cancer (CRC), hepatocellular carcinoma (HCC), and pancreatic cancer (PC). These cancers contribute significantly to the burden of death worldwide, especially for CRC, with more than 1.9 million new cases estimated in the Global Cancer (GLOBOCAN) 2020 statistics and ranking third for incidence and second for mortality globally.¹ Each gastrointestinal tract tumor has distinct biological characteristics, such as cellular proliferation, disruption of cell metabolism, invasion, metastasis, promotion of angiogenesis, unique follow-up therapy, and prognosis. Although the pathogenesis of these cancers has been extensively studied, much remains unclear and further studies related to cancer-associated molecules are needed.

The chemokine-like factor super family (CKLFSF) consists of nine members: CKLF and CKLFSF 1–8, and their encoding proteins are structurally similar to chemokines.² CKLF1 was first cloned from a leukemia cell line stimulated by phytohemagglutinin (PHA) and reported by the Human Disease Gene Research Center of Peking University in 2001.³ Subsequently, CKLFSF 1–8 were demonstrated through analysis combining CKLF2 cDNA and protein sequence analysis with experimental verification in 2003. Owing to the presence of a MARVEL (MAL and related proteins for vesical trafficking and membrane link) domain, CKLFSF1-8 was renamed CKLF-like MARVEL transmembrane domain containing 1–8 (CMTM1-8).

Since the first member was cloned, there have been abundant studies on the relationships between the CMTM family of proteins and human cancers. It has been reported that the CMTM family has a large potential prognostic value for multiple cancers owing to its differential expression between tumor and normal tissues.⁴⁻⁸ Meanwhile, upregulated or downregulated expression of these family proteins was related to advanced tumor stage, tumor grade, metastasis, and overall survival. Studies have also reported that these proteins play critical roles in antitumor immunity.⁹,¹⁰ For example, CMTM4/6 reduces...
PD-L1 ubiquitination, increases protein half-life, and enhances the ability of PD-L1-expressing tumor cells to inhibit T cells. These findings indicate that some CMTM family members are potential therapeutic targets for the treatment of human cancer. Owing to the diverse structure and function of CMTM family members and obvious heterogeneity of different human cancers, CMTM1-8 has distinct effects on malignant tumors, oncogenes, and tumor suppressors. This review briefly outlines the structure and function of CMTM1-8 in human cancers and details the latest advances in the field regarding its roles in carcinogenesis and its potential clinical value, with a primary focus on gastrointestinal tract cancers.

**Characteristics of CMTM Family**

CMTM members are located on different chromosomes: CMTM1-4 cluster on 16q22.1, CMTM5 cluster on 14q11.2, and CMTM6-8 cluster on 3p22.3. The CMTM family is structurally and functionally characterized, similar to classic chemokines and transmembrane-4 superfamily (TM4SF). Among these, CMTM1 contains a C-C motif and shows higher sequence identity with chemokines, while CMTM8 has 39.3% amino acid similarity with TM4SF11, and the biological characteristics of CMTM2-7 are between those of chemokines and TM4SF. As a recently discovered gene family, the transcription of CMTM members and their quaternary structures has not been identified. Individual CMTM family members have different alternative RNA splicing forms and further make up several isoforms. We summarized the MARVEL domain of each CMTM1-8 in Figure 1 based on the AlphaFold Protein Structure Database (https://alphafold.ebi.ac.uk/) and GeneCards, the human gene database (https://www.genecards.org/).

CMTM1-8 each has a MARVEL domain, a conserved M-shaped topology: four transmembrane-helix region architectures with cytoplasmic N- and C-terminal regions (Figure 1). Thus, their functional production could be related to the cholesterol-rich membrane apposition events in various biological processes, such as the biogenesis of vesicular transport carriers or tight junction regulation. As MARVEL was initially identified in proteins of the myelin and lymphocyte (MAL), physins, gyrins, and occludin families, the MARVEL domain seems to be related to complex diseases, such as inflammation and schizophrenia. To date, CMTM1, 2, 3, and 4 are highly expressed in the testis and compartments of the bone marrow and peripheral blood cells, such as activated peripheral blood monocytes, while CMTM3, 5, 7, and 8 are broadly expressed in healthy adult and fetal tissues. Therefore, CMTM1-8 appears to be involved in various human diseases, including atopic dermatitis, autoimmune, cerebral ischemia, peripheral neuropathy, cardiovascular diseases, and spermatogenesis dysfunction. We reviewed the relevant literature, and the research advances on the CMTM family and human cancers are summarized in Table 1.

Several biological processes, such as DNA methylation and microRNAs, as well as transcriptional regulation molecules, such as NF-κB, p53, and SOX10, regulate the expression of CMTM family members. DNA methylation is another important regulator of CMTM family member expression. For example, CpG methylation can inactivate the CMTM5 gene in various carcinoma cell lines, such as oral squamous cell carcinoma, breast carcinoma, and myeloid leukemia. Frequent CMTM7 promoter methylation was detected in ESCC and NPC cell lines with downregulated or silenced CMTM7, but not in other tumor cell lines. Most notably, methylation was not detected in several cancer cell lines (including KYSE180), in which CMTM7 was barely observable. This suggests that other genetic alterations or histone modifications may also be responsible for the downregulation of CMTM7.

In terms of transcriptional regulation molecules, the promoter sequence of CMTM7 contains numerous regions that are highly similar to the HMG-box sequence. In line with this, SOX gene family members containing a DNA-binding domain have been reported to regulate cell differentiation and tissue formation as a highly conserved transcription factor. According to the TCGA database, a positive correlation between CMTM7 and SOX10 mRNA expression levels was detected. Additionally, knockdown of SOX10 by transfection with siRNA significantly downregulated CMTM7 expression at the mRNA and protein levels in GC cell lines. Thus, SOX10 may also be a potential regulator of the expression of CMTM family members. In another study, Guan et al showed that miR-10b-3p, which plays an oncogenic role, was dramatically upregulated in HCC cell lines (HepG2), and the expression of CMTM5 was significantly suppressed.
Esophageal Cancer (EC)

EC is one of the most common malignant diseases, with approximately 604,000 new cases and 544,000 deaths worldwide per year. Unlike other gastrointestinal tract cancers, EC has two common histologic subtypes: esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), which have different etiologies and geographic variations. A recent study demonstrated that the expressions of CMTM3 and CMTM4 at the mRNA and protein levels were significantly decreased in ESCC tissues compared to those in matched non-tumor tissues. Meanwhile, CMTM3 expression was significantly correlated with lymph node metastasis and clinical stage in ESCC, and lower

---

### Figure 1

CMTM family members structure according to AlphaFold Protein Structure Database and GeneCards.

**Notes:** AlphaFold Protein Structure Database: [https://alphafold.ebi.ac.uk/](https://alphafold.ebi.ac.uk/); GeneCards: [https://www.genecards.org/](https://www.genecards.org/). (Structure prediction last updated on 9 December 2021).

---

**CMTM Family Members in Digestive System Cancers**

**Esophageal Cancer (EC)**

EC is one of the most common malignant diseases, with approximately 604,000 new cases and 544,000 deaths worldwide per year. Unlike other gastrointestinal tract cancers, EC has two common histologic subtypes: esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), which have different etiologies and geographic variations. A recent study demonstrated that the expressions of CMTM3 and CMTM4 at the mRNA and protein levels were significantly decreased in ESCC tissues compared to those in matched non-tumor tissues. Meanwhile, CMTM3 expression was significantly correlated with lymph node metastasis and clinical stage in ESCC, and lower
Table 1 CMTM Family in Human Cancers

| Gene   | Cancer                     | Expression (Tumor vs Normal) | Function                                                                 | Signaling Pathway          | Reference |
|--------|----------------------------|------------------------------|--------------------------------------------------------------------------|----------------------------|-----------|
|        | CMTM1                      |                              |                                                                          |                            |           |
|        | Breast carcinoma           | Higher                       | CMTM1_v17 promotes cell proliferation                                    | TNF-α, NF-κB               | [33]      |
|        | NSCLC                      | Higher                       | Associated with chemoresistance and poor prognosis.                      |                            | [6]       |
|        | HCC                        | Higher                       | Correlated with poorer overall survival                                 |                            | [33,34]  |
|        | GC                         | Higher (mRNA)*               | Correlated with shorter overall survival                                | -                          | [35]      |
|        | Globioma                   | n.s.                         | Correlated with shorter overall survival                                | -                          | [36]      |
|        | Lymphoma                   | -                            | Induce cell apoptosis                                                    |                            | [37]      |
|        | CMTM2                      | HCC                          | Downregulated CMTM2 promotes EMT                                         |                            | [38,39]  |
|        | GC                         | n.s. (mRNA)*                 |                                                                          |                            | [35]      |
|        | HCC                        | Lower                        |                                                                          |                            |           |
|        | ESCC                       | Lower                        | Inhibits the proliferation; Regulated EMT                               | JAK2/STAT3                 | [40,41]  |
|        | GC                         | Lower;                       | Inhibit tumorigenicity                                                   | EGFR, Rab5; STAT3/Twist1   | [5,35,42–44] |
|        | PC                         | Higher (mRNA)*               | Inhibits cell migration and invasion                                     | JAK2/STAT3                 | [45]      |
|        | HCC                        | Lower                        | Promotes cell proliferation and migration                                | EGFR, Rab5; STAT3/Twist1   | [46]      |
|        | GC                         | Higher (mRNA)*               | Associated with a favorable prognosis                                    | JAK2/STAT3                 | [36]      |
|        | Prostate cancer            | Lower                        | Correlated with shorter overall survival                                | JAK2/STAT3                 | [51]      |
|        | Renal cell carcinoma       | Lower                        | Associated with a favorable prognosis                                    | JAK2/STAT3                 |           |
|        | Renal cell carcinoma       | Lower                        |Associated with a favorable prognosis                                    | JAK2/STAT3                 |           |
|        | Prostate cancer            | Lower                        | Associated with a favorable prognosis                                    | JAK2/STAT3                 |           |
|        | Renal cell carcinoma       | Lower                        | Associated with a favorable prognosis                                    | JAK2/STAT3                 |           |
|        | CMTM3                      | HCC                          | Tumor suppressor; An important prognostic and diagnostic marker; Facilitates escape from antitumor T-cell immunity and tumor growth |                            | [57–59]  |
|        | GC                         | n.s. (mRNA)*                 | Tumor suppressor; An important prognostic and diagnostic marker; Facilitates escape from antitumor T-cell immunity and tumor growth |                            | [35]      |
|        | CRC                        | Lower                        | Tumor suppressor; An important prognostic and diagnostic marker; Facilitates escape from antitumor T-cell immunity and tumor growth |                            | [60]      |
|        | Clear cell renal cell carcinoma | Lower                  | Tumor suppressor; An important prognostic and diagnostic marker; Facilitates escape from antitumor T-cell immunity and tumor growth |                            | [61,62]  |
|        | HNSCC                      | Higher                       | Tumor suppressor; An important prognostic and diagnostic marker; Facilitates escape from antitumor T-cell immunity and tumor growth |                            |           |
|        | HeLa cell                  | Lower                        | Tumor suppressor; An important prognostic and diagnostic marker; Facilitates escape from antitumor T-cell immunity and tumor growth |                            |           |
|        | Globioma                   | Lower (mRNA)*                | Tumor suppressor; An important prognostic and diagnostic marker; Facilitates escape from antitumor T-cell immunity and tumor growth |                            |           |
|        | CRC                        | Lower                        | Inhibits cell proliferation and migration                                | AKT, ERK1/2, STAT3         | [63]      |
|        | Clear cell renal cell carcinoma | Lower                  | Inhibits cell proliferation and migration                                | AKT, ERK1/2, STAT3         | [64]      |
|        | HNSCC                      | Higher                       | Inhibits cell proliferation and migration                                | AKT, ERK1/2, STAT3         | [65]      |
|        | HeLa cell                  | Higher                       | Inhibits cell proliferation and migration                                | AKT, ERK1/2, STAT3         | [66–68]  |
|        | Globioma                   | Lower (mRNA)*                | Regulates EMT and PD-L1 expression                                       | PI3K/AKT                   | [69,70]  |
|        | Clear cell renal cell carcinoma | Lower                  | Regulates EMT and PD-L1 expression                                       | PI3K/AKT                   |           |
|        | HNSCC                      | Higher                       | Regulates EMT and PD-L1 expression                                       | PI3K/AKT                   |           |
|        | HeLa cell                  | Higher                       | Regulates EMT and PD-L1 expression                                       | PI3K/AKT                   |           |
|        | Globioma                   | Lower (mRNA)*                | Regulates EMT and PD-L1 expression                                       | PI3K/AKT                   |           |
|        | CMTM5                      | HCC                          | Tumor suppressor; An important prognostic and diagnostic marker; Facilitates escape from antitumor T-cell immunity and tumor growth |                            |           |
|        | Breast carcinoma           | Lower                        | Tumor suppressor; An important prognostic and diagnostic marker; Facilitates escape from antitumor T-cell immunity and tumor growth |                            |           |
|        | Prostate cancer            | Lower                        | Tumor suppressor; An important prognostic and diagnostic marker; Facilitates escape from antitumor T-cell immunity and tumor growth |                            |           |
|        | Cervical carcinoma cells   | Lower                        | Tumor suppressor; An important prognostic and diagnostic marker; Facilitates escape from antitumor T-cell immunity and tumor growth |                            |           |
|        | Renal cancer               | Lower                        | Tumor suppressor; An important prognostic and diagnostic marker; Facilitates escape from antitumor T-cell immunity and tumor growth |                            |           |
|        | Cervical carcinoma cells   | Lower                        | Tumor suppressor; An important prognostic and diagnostic marker; Facilitates escape from antitumor T-cell immunity and tumor growth |                            |           |

(Continued)
| Gene | Cancer | Expression (Tumor vs Normal) | Function | Signaling Pathway | Reference |
|------|--------|-----------------------------|----------|-----------------|-----------|
| OSCC | Epithelial ovarian cancer | Lower | Tumor suppressor activity | - | [28] |
| PC cells | Lower | | - | | [73] |
| Leukemia | Lower | | induces apoptosis | | [74] |
| Multiple myeloma progression | Lower | | Tumor suppressive function | | [30] |
| | | | Inhibits the proliferative activity | | [75,76] |
| CMTM6 | HCC | Lower [55]; Higher | Related to inflammatory cell density; Promotes migration, invasion, and EMT; Stabilizing PD-L1; Associated with tumor recurrence. | B7 family, Vimentin, PD-L1 | [77–81] |
| | GC | Higher | a useful prognostic indicator | | [39,40] |
| | CRC | Higher | Associated with an active immune microenvironment, a favorable prognosis. | | [84,85] |
| | NSCLC | Lower in lung adenocarcinoma | Correlated with PD-L1 expression and immune cells infiltration | Wnt/β-catenin, TGFβ; ENO-1/ AKT/GSK3β; ERK1/2 | [4,86–89] |
| | HNSCC | Higher | Promotes cell proliferation and invasion; drives cisplatin resistance; Induced M2-like macrophages polarization | | [90–94] |
| Gliomas | Higher | Regulating T cell activation and antitumor and responses | | | [7] |
| Undifferentiated pleomorphic sarcoma | Higher (mRNA)* | Correlated with the strong expression of PD-L1 | | | [95] |
| | Glioblastoma | | | | [36] |
| CMTM7 | HCC | Lower | Inhibits cell growth and migration | EGFR-AKT, Rab5 | [96] |
| | GC | Lower | Inhibits cell proliferation and tumor growth | | [31] |
| | NSCLC | CMTM7 knockdown increases tumorigenicity, a potential tumor suppressor | | | [97,98] |
| CMTM8 | HCC | Lower | Down-regulation induces EMT, regulating tumor cell migration | | [99] |
| | GC | Lower(HC) Higher (mRNA)* | Downregulated CMTM8 correlates with Poor prognosis | HGF/ c-MET/ERK | [100] |
| | Bladder cancer | Lower | Inhibits the carcinogenesis and progression | | [8,101] |
| | PC | LPA1 and CMTM8 were co-localized | Mediates lysophosphatidic acid-induced metastasis | LPA1-associated partner | [114] |
| Renal cell carcinoma | Lower | | | | [103] |
| Glioblastoma | Lower (mRNA) | - | | | [36] |

**Note:** *Bioinformatics analysis.

**Abbreviations:** HCC, hepatocellular carcinoma; GC, gastric carcinoma; ESCC, esophageal squamous cell carcinoma; NSCLC, non-small cell lung cancer; HNSCC, head and neck squamous cell carcinoma; OSCC, oral squamous cell carcinoma; PC, pancreatic cancer; CRC, colorectal cancer.
CMTM3 expression correlated with shorter survival time for ESCC patients. This indicates that the expression of CMTM3 in resected tumors may be an effective prognostic biomarker. CMTM5-v1 was reported to be reduced or silenced in 12 of 16 ESCC cell lines, while CMTM7 is frequently silenced or downregulated in eight of 18 ESCC cell lines (44.4%), such as EC109, KYSE410, and KYSE180. Meanwhile, promoter methylation of CMTM5 and CMTM7 was also detected in esophageal tumor tissues and cell lines. Overexpression of CMTM7 by adenovirus infection promoted the internalization of epidermal growth factor receptor (EGFR) and further downregulated p-AKT. CMTM7 also inhibited cell proliferation and motility in KYSE410 and KYSE180 cells by inducing G1/S cell cycle arrest by upregulating p27 and downregulating cyclin-dependent kinase 2 (CDK2) and 6 (CDK6). Interestingly, MAL proteins, which are essential components of the cellular polarized sorting system, have been reported to suppress cell invasion and tumorigenicity of cervical squamous cell cancers, suggesting that it may be a candidate tumor suppressor gene. It is possible that CMTM3, 5, and 7 act as novel functional critical tumor-suppressor genes in ESCC. At present, there are no studies on CMTM1-8 in EAC.

Gastric Carcinoma (GC)
GC remains a critical cancer worldwide and is responsible for over 1,089,103 new cases and an estimated 768,793 deaths in 2020, ranking fifth for incidence and fourth for mortality globally. Although GC is generally reported as an entity, it can be divided into two topographical subsites: cardia adenocarcinoma and non-cardia adenocarcinoma. The two entities differ in their risk factors, carcinogenesis, and epidemiologic patterns. Recently, an analysis using bioinformatics methods showed that the mRNA levels of CMTM1, 3, 6, 7, and 8 were upregulated in GC, but CMTM2, 4, and 5 were not significantly different between GC samples and normal tissue. Additionally, the mRNA expression of CMTM family members exhibited strong relationships with various clinical characteristics of patients, such as tumor stage, metastatic lymph node status, and H. pylori status. For example, elevated CMTM3 and 5 mRNA levels were significantly associated with poor overall survival, while upregulated mRNA expression of CMTM2, 4, and 6 was significantly associated with better overall survival. These results indicate that the CMTM family expression pattern could be a novel prognostic factor for patients with GC.

In contrast, CMTM3 was reported as a tumor suppressor gene in GC patients with different tumor stages using immunohistochemistry (IHC). High expression of CMTM3 might correlate with favorable prognosis of patients, and CMTM3 expression significantly affected the migration and invasion of gastric cell lines (AGS and SGC-7901 cells). CMTM3 not only inhibited EGF-mediated tumorigenicity by inducing Rab5 activity, but also suppressed GC metastasis via the STAT3/Twist1/EMT pathway. Meanwhile, patients with diffuse-type GC and higher CMTM2 expression had a better overall survival, indicating that CMTM2 expression could predict the prognostic outcomes in diffuse-type GC, but not in intestinal-type GC. CMTM5-v1 was reduced or silenced in eight of 10 GC cell lines.

CMTM6, 7, and 8 are broadly expressed in normal human epithelial cell lines. A recent study showed that GC patients with high CMTM6 expression had shorter overall survival (OS), and the co-expression of CMTM6 and PD-L1 may be used to judge the prognosis of GC patients. Although only one of 16 GC lines (6.25%) showed CMTM7 downregulated expression, the downregulation of CMTM7 was detected in GC tissues using tissue microarrays. Interestingly, silencing CMTM7 expression could increase the proliferation and promote tumorigenesis of GC cells, while the overexpression of SOX10-dependent CMTM7 significantly inhibited the tumor growth of GC. Contrary to the bioinformatics results of the Oncomine database, IHC results showed that the positive rate of CMTM8 protein expression was significantly decreased in GC samples compared to that in adjacent non-tumor tissues, and its expression was correlated with tumor differentiation and node metastasis stage. The reason for this discrepancy may be that there are some differences between mRNA and protein expression of CMTM8 regarding posttranscriptional regulation. CMTM8 overexpression significantly decreased the proliferation of the gastric cell line BGC823 and the expression of EGFR. In addition, multiple gene set enrichment analyses (GSEA) showed that CMTM8 could regulate the Ca^2+ signaling pathway, cell adhesion molecules, and interaction of cytokines and their receptors in GC progression. Therefore, CMTM3, 7, and 8 tend to be regarded as tumor suppressors in the development of GC.
Hepatocellular Carcinoma (HCC)

Primary HCC is the sixth most commonly diagnosed malignancy and the third leading cause of cancer-related deaths worldwide, with 905,677 new cases and 830,180 deaths in 2020.\(^1\) The liver, one of the most common hematogenous metastasis organs of gastrointestinal malignancies, has attracted more interest from the community and research on CMTMs. Recent studies have revealed that CMTMs are closely related to HCC, and the members might represent promising targets for HCC diagnosis and treatment. Based on the Human Protein Atlas and bioinformatics analysis, a higher level of CMTM1 mRNA expression was associated with a lower survival probability in patients with HCC.\(^34\) Although CMTM2 is not a prognostic index in HCC according to data from the Human Protein Atlas, several studies have revealed that CMTM2 expression is correlated with HCC pathological grades.\(^38\) In addition, knockdown of CMTM2 promoted invasion and migration of HCC cells (Huh-7 and SMMC7721) by inducing the epithelial-mesenchymal transition (EMT) process.\(^39\) The Human Protein Atlas showed that CMTM3 expression was higher in liver tumor tissues and was associated with poor prognosis.\(^34\) However, Li et al reported that the expression of CMTM3 was lower in HCC cell lines (HepG2, 97H, Hep3B, and HCCLM3), and CMTM3 inhibited the proliferation and metastasis of HCC cells by suppressing the JAK2/STAT3 signaling pathway.\(^40\) Moreover, Zhao et al suggested that CMTM3 may participate in regulating the tumor microenvironment in an orthotopic HCC mouse model.\(^107\)

A case-control study in the southern Chinese population showed a strong correlation between rs3811178 in CMTM5 and the risk of HCC.\(^108\) Compared with the paired adjacent non-tumor tissues, CMTM5 was significantly reduced in HCC tissues, as well as in Huh7, Hep3B, HepG2, and SMMC-7721 cell lines. CMTM5 overexpression significantly inhibited cell proliferation and metastasis in Huh7 cells by inhibiting PI3K/AKT signaling.\(^65\) In addition, a previous study demonstrated that CMTM5 expression could be restored in HCC treated with PXD101, a histone deacetylase inhibitor.\(^109\) Thus, CMTM5 may be a valuable therapeutic target for HCC treatment.

As for the CMTM4 expression in HCC, there are two inconsistent opinions. One study reported a lower CMTM4 protein expression level in HCC tissues,\(^57\) while another two studies showed upregulation of CMTM4 at the mRNA and protein levels.\(^58,59\) Furthermore, the upregulated CMTM4 expression in HCC facilitates escaping from antitumor T-cell immunity and contributes to an immunosuppressive tumor microenvironment.\(^59\) Similar to CMTM4, CMTM6 expression was downregulated\(^28\) or upregulated\(^30,110\) in HCC tissues. The reasons for the contradiction between these studies are still ambiguous; however, small-scale specimens, heterogeneity of tumor tissue, and observational bias are possible factors. Interestingly, immunoreactive cellular distribution showed positive CMTM6 expression in all proliferative lesions from the early stage in the piperonyl butoxide (PBO)-induced hepatocarcinogenesis mouse model.\(^111\) Meanwhile, CMTM6 had a high concordance ratio with CK8/18+ foci, a useful immunohistochemical marker for detecting hepatocellular proliferative lesions in mice.\(^112\) Individuals from Guangxi, China, with the rs164207 AA genotype of CMTM6, have a higher risk of HCC than those with the CC genotype.\(^108\) These results suggest that CMTM6 may play important roles in the early stages of carcinogenesis and could be used as a detection marker for hepatocellular proliferative lesions.\(^111\)

Recent studies have shown that CMTM6 expression is upregulated in HCC tissues, and its overexpression increases cell proliferation and enhances cell invasion and migration and induces epithelial–mesenchymal transition (EMT) mechanistically by stabilizing vimentin.\(^80\) In addition, the co-expression of CMTM6/PD-L1 can regulate inflammatory cell density\(^77\) and has a close relationship with tumor recurrence.\(^81\) Given the participation of CMTM6 in PD-L1 stabilization,\(^9,10\) combined treatment with anti-CMTM6 and anti-PD-L1 may be a new method to enhance the therapeutic benefits in HCC.

The expression of CMTM7 was significantly reduced in liver cancer tissues, but was not correlated with TNM stage or metastasis. Overexpression of CMTM7 inhibited the proliferation and migration of HCC cell lines (SK-HEP-1). Thus, CMTM7 functions as a tumor suppressor in liver cancer by suppressing cell cycle progression.\(^96\)

Pancreatic Cancer (PC)

PC is generally regarded as one of the most lethal malignancies, with a median overall survival of 6 months and a 5-year survival rate of less than 5%.\(^102\) The 2020 GLOBOCAN statistics showed that in 185 countries pancreatic cancer accounts for almost as many deaths (466,003) as cases (495,773) due to its poor prognosis.\(^1\) Using a pancreatic cancer tissue microarray, CMTM5 was significantly decreased in pancreatic cancer tissues and
was directly correlated with the differentiation status of tumors. Restoration of CMTM5-v1 not only induced apoptosis of pancreatic cancer cells (MIA PaCa-2), but also had synergistic effects with TNF-A. Pancreatic stellate cell (PSC)-derived exosomes, miR-5703, promoted cell proliferation, and its inhibitor suppressed the function of exosomes. Furthermore, CMTM4 was downregulated by miR-5703 directly bound to the CMTM4 3’UTR, and CMTM4 knockdown promoted cell proliferation owing to the PAK4-activated PI3K/AKT pathway in pancreatic cancer cells. A recent publication reported that CMTM8 protein was co-localized with lysophosphatidic acid (LPA)-1 in pancreatic cancer cells and markedly increased after LPA treatment. However, CMTM8 mRNA abundance showed no significant change in BxPC-3 and PANC-1 cells treated with LPA, implying that LPA treatment stabilizes CMTM8 protein. Meanwhile, depletion of CMTM8 knockdown significantly inhibited the migration and invasion of pancreatic cancer cells in vivo. To date, with the exception of CMTM4, 5, and 8, no reports on the role of the other CMTM family members in pancreatic cancer are available. Further studies are needed to elucidate the underlying mechanisms of CMTMs in the development of pancreatic cancer.

**Colorectal Cancer (CRC)**

CRC ranks third in terms of incidence, but second in terms of mortality worldwide. In 2020, more than 1.9 million new CRCs were estimated to occur. However, after a large number of studies were reviewed, only a few studies have focused on the roles of CMTMs in CRC. CMTM3 is silenced or downregulated in colon cell lines and primary tumors, consistent with the results from the Cancer Genome Atlas (TCGA) database, while re-expression of CMTM3 can inhibit cell growth and cause apoptosis in human cancer cells. Xue et al found that CMTM4 was also frequently reduced in CRC, and CMTM4 overexpression was associated with increased overall survival rates. Overexpression of CMTM4 inhibited cell proliferation and migration in SW480 cells, and knockdown of CMTM4 showed the opposite effects in HT-29 cells. The phosphorylation levels of cell signaling molecules essential for CRC progression, including AKT, ERK1/2, and STAT3, were decreased by CMTM4 overexpression in SW480 cells and increased by CMTM4 knockdown in HT-29 cells. CMTM7 was methylated in primary esophageal carcinomas and GC, but not in any of the 11 colon tumor tissues. Since a protective role for PD-L1 was reported in Nature, the latest research has shown that CMTM6 is crucial in regulating the immune microenvironment in CRC, and the co-expression of CMTM6 and PD-L1 can be used to stratify the risk of progression in CRC patients. Meanwhile, the expression status of CMTM6 in M2 macrophages may more accurately predict the drug response to PD-1/PD-L1 inhibitors in CRC patients. To date, the roles of other CMTM members in CRC, except for CMTM3, 4, and 6, are largely unknown.

**Conclusion**

To summarize, CMTM family members have different expression profiles in human cancer samples and normal tissues and have different functions in the development and progression of gastrointestinal tract cancers. Meanwhile, they were reported to be tumor suppressors or tumor promoters owing to their relationships with the regulation of the cell cycle, EMT process, and EGFR signaling pathway (Table 2). The heterogeneity of different tumors and distinct molecular structures of each CMTM member make this family in human cancers controversial. With the exception of CMTM4/6, demonstrated to be PD-L1 regulators and may be potential immunotherapy targets, the mechanism of the other members remains partially understood. Hence, the CMTM family and their functions, mechanisms, and related signaling pathways in gastrointestinal tract cancers need to be further explored as these could provide a new viewpoint for the diagnosis or therapeutic targets of human cancers.

**Statements and Declarations**

This study was reviewed and approved by The Institutional Review Board of Hebei Medical University.

**Funding**

This study was supported by the Natural Science Foundation of Hebei Province (No. H2021206395).
Table 2 The Roles of CMTM Family in Gastrointestinal Tract Cancers

| Gene   | EC | HCC  | GC  | PC  | CRC |
|--------|----|------|-----|-----|-----|
| CMTM1  | NA | NA   | Promoter | NA | NA |
| CMTM2  | NA | Suppressor | NA | NA | NA |
| CMTM3  | Suppressor | Suppressor | Suppressor | Suppressor | NA |
| CMTM4  | NA | Promoter/suppressor | NA | NA | NA |
| CMTM5  | NA | Suppressor | NA | Suppressor | NA |
| CMTM6  | NA | Suppressor | NA | NA | NA |
| CMTM7  | Suppressor | NA | NA | NA | NA |
| CMTM8  | NA | Suppressor | Suppressor | Promoter | NA |

Disclosure

The authors declare no conflicts of interest in this work.

References

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
2. Han W, Ding P, Xu M, et al. Of eight genes encoding chemokine-like factor superfamily members 1–8 (CKLFSF1-8) by in silico cloning and experimental validation. Genomics. 2003;81(6):609–617. doi:10.1016/s0888-7543(03)00095-8
3. Han W, Lou Y, Tang J, et al. Molecular cloning and characterization of chemokine-like factor 1 (CKLF1), a novel human cytokine with unique structure and potential chemotactic activity. Biochem J. 2001;357(Pt1):127–135. doi:10.1042/0264-6021;
4. Hou X, He S, Zhang D, Yang C, Shi Y, Zhang K. Expression and clinical significance of CMTM6 in nonsmall cell lung cancer. DNA Cell Biol. 2020;1343. doi:10.1089/dna.2020.5564
5. Su Y, Lin Y, Zhang L, et al. CMTM3 inhibits cell migration and invasion and correlates with favorable prognosis in gastric cancer. Cancer Sci. 2014;105(1):26–34. doi:10.1111/cas.12304
6. Si J, Zhang P, Tian D, et al. CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer. World J Surg Oncol. 2017;15(1):34. doi:10.1186/s12957-016-1094-z
7. Guan X, Zhang C, Zhao J, Sun G, Song Q, Jia W. CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas. ElBioMedicine. 2018;35:233–243. doi:10.1016/j.ebiom.2018.08.012
8. Zhang S, Pei X, Hu H, et al. Functional characterization of the tumor suppressor CMTM8 and its association with prognosis in bladder cancer. Tumour Biol. 2016;37(5):6217–6225. doi:10.1007/s13277-015-4508-6
9. Burr ML, Sparbier CE, Chan YC, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 2017;549(7670):101. doi:10.1038/nature23643
10. Mezzadra R, Sun C, Jae LT, et al. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature. 2017;549(7670):106–110. doi:10.1038/nature23669
11. Duan HJ, Li XY, Liu C, Deng XL. Chemokine-like factor-like MARVEL transmembrane domain-containing family in autoimmune diseases. Chin Med J. 2020;133(8):951–958. doi:10.1097/CMD.0000000000000747
12. Wu K, Li X, Gu H, Yang Q, Liu Y, Wang L. Research Advances in CKLF-like MARVEL Transmembrane Domain-containing Family in Non-small Cell Lung Cancer. Int J Biol Sci. 2019;15(12):2576–2583. doi:10.7150/ijbs.37337
13. Sánchez-Pulido L, Martin-Belmonte F, Valencia A, Alonso MA. MARVEL: a conserved domain involved in membrane apposition events. Trends Biochem Sci. 2006;21(7):599–601. doi:10.1016/j.tibs.2006.04.022
14. Zhong J, Wang Y, Qiu X, et al. Characterization and expression profile of CMTM3/CKLFSF3. J Biochem Mol Biol. 2006;39(5):537–545. doi:10.5483/bmbrep.2006.39.5.537
15. Song HS, Shi S, Lu XZ, et al. Intracellular CMTM2 negatively regulates human immunodeficiency virus type-1 transcription through targeting the transcription factors AP-1 and CREB. Chin Med J. 2010;123(17):2440–2445.
16. Wang L, Wu C, Zheng Y, et al. Molecular cloning and characterization of chemokine-like factor-suppressor-like family member 1 (CMTM1), a novel human gene with at least 23 alternative splicing isoforms in testis tissue. Int J Biochem Cell Biol. 2004;36(8):1492–1501. doi:10.1016/j.biocel.2003.11.017
17. Li H, Li J, Su Y, et al. A novel 3p22.3 gene CMTM7 represses oncopgenic EGFR signaling and inhibits cancer cell growth. Oncogene. 2014;33(24):3109–3118. doi:10.1038/onc.2013.282
18. Yang KY, Chen X, Sun YC, Ma CL, Qian G. Chemokine-like factor 1 (CLFK1) is over-expressed in patients with atopic dermatitis. Int J Biol Sci. 2013;9(8):759–765. doi:10.7150/ijbs.6291
19. Kong LL, Wang ZY, Hu JF, Yuan YH, Li H, Chen NH. Inhibition of chemokine-like factor 1 improves blood-brain barrier dysfunction in rats following focal cerebral ischemia. Neurosci Lett. 2016;627:192–198. doi:10.1016/j.neulet.2016.06.003
20. Kong LL, Wang ZY, Hu JF, et al. Inhibition of chemokine-like factor 1 protects against focal cerebral ischemia through the promotion of energy metabolism and anti-apoptotic effect. Neurochem Int. 2014;76:91–98. doi:10.1016/j.neuint.2014.07.004
21. Kong LL, Hu JF, Zhang W, et al. Expression of chemokine-like factor 1 after focal cerebral ischemia in the rat. Neurosci Lett. 2011;505(1):14–18. doi:10.1016/j.neulet.2011.09.031
48. Xue L, Ouyang Q, Li J, et al. Different roles for p16(INK) (4a) –Rb pathway and INK4a/ARF methylation between adenocarcinomas of gastric and distal stomach.

47. Liu W, Li J, Zhang D, et al. Trefoil factor 1 and gastrokine 2 inhibit Helicobacter pylori-induced proliferation and inflammation in gastric cardia.

46. Zhou Z, Ma Z, Li Z, et al. CMTM3 Overexpression Predicts Poor Survival and Promotes Proliferation and Migration in Pancreatic Cancer.

45. Wang Y, Li J, Cui Y, et al. CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and membrane link transmembrane domain-containing protein 2 in rats with varicocele.

44. Hu F, Yuan W, Wang X, et al. CMTM3 is reduced in prostate cancer and inhibits migration, invasion and growth of LNCaP cells.

43. Yuan W, Li T, Mo X, et al. Knockdown of CMTM3 promotes metastasis of gastric cancer via the STAT3/Twist1/EMT signaling pathway.

42. Zhang XW, Dun YJ, Tang X, et al. [Expression of chemokine like factor-like myelin and lymphocyte and related proteins for vesicle trafficking and membrane link transmembrane domain-containing protein 2 in rats with varicocele]. Beijing Da Xue Xue Bao Yi Xue Ban. 2016;48(4):579–583. Chinese.

41. Lu M, Luo F, Tian X, Yin S, Zhou L, Zheng S. miR-135b-5p promotes gastric cancer progression by targeting CMTM3.

40. Li M, Luo F, Tian X, Yin S, Zhou L, Li L. miR-135b-5p promotes gastric cancer progression by targeting CMTM3.

39. Shao L, Cui Y, Li H, et al. CMTM5 exhibits tumor suppressor activities and is frequently silenced by methylation in carcinoma cell lines. Clin Cancer Res. 2007;13(19):5756–5762. doi:10.1158/1078-0432.CCR-06-3082

38. Guo X, Zhang S, Tan S, et al. Downregulated CMTM2 Poses Potential Clinical Significance in Hepatocellular Carcinoma. Targets Ther. 2020;11(4):579–583. doi:10.20892/j.issn.2095-3941.2020.0032

37. Liang Z, Xie J, Huang L, et al. Comprehensive analysis of the prognostic value of the chemokine-like factor-like MARVEL transmembrane domain-containing family in gastric cancer. Front Oncol. 2020;10:595973. doi:10.3389/fonc.2020.595973

36. Delic S, Thay A, Schulze M, et al. Systematic investigation of CMTM family genes suggests relevance to glioblastoma pathogenesis and CMTM1 and CMTM3 as priority targets. Genes Chromosomes Cancer. 2015;54(7):433–443. doi:10.1002/gcc.22255

35. Li M, Luo F, Tian X, Yin S, Zhou L, Zheng S. Chemokine-Like Factor-Like MARVEL Transmembrane Domain-Containing Family in Hepatocellular Carcinoma: latest Advances. Front Oncol. 2020;10:595973. doi:10.3389/fonc.2020.595973

34. Guo X, Zhang S, Tan S, et al. Downregulated CMTM2 Poses Potential Clinical Significance in Hepatocellular Carcinoma. DNA Cell Biol. 2020;39(4):683–689. doi:10.1089/dna.2019.5237

33. Zhang S, Tian R, Bei C, et al. Down-Regulated CMTM2 Promotes Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma. Onco Targets Ther. 2020;13:5731–5741. doi:10.2147/OTT.S250370

32. Zhang S, Tian R, Bei C, et al. Down-Regulated CMTM2 Promotes Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma. Onco Targets Ther. 2020;13:5731–5741. doi:10.2147/OTT.S250370

31. Li M, Luo F, Tian X, Yin S, Zhou L, Zheng S. Chemokine-Like Factor-Like MARVEL Transmembrane Domain-Containing Family in Hepatocellular Carcinoma: latest Advances. Front Oncol. 2020;10:595973. doi:10.3389/fonc.2020.595973

30. Niu J, Li H, Zhang Y, et al. Aberrant expression of CKLF-like MARVEL transmembrane member 5 (CMTM5) by promoter methylation in myocardial leukemia. Leuk Res. 2011;35(6):771–776. doi:10.1016/j.leukres.2010.11.023

29. Shao L, Cui Y, Li H, et al. CMTM5 exhibits tumor suppressor activities and is frequently silenced by methylation in carcinoma cell lines. Clin Cancer Res. 2007;13(19):5756–5762. doi:10.1158/1078-0432.CCR-06-3082

28. Zhang XW, Dun YJ, Tang X, et al. [Expression of chemokine like factor-like myelin and lymphocyte and related proteins for vesicle trafficking and membrane link transmembrane domain-containing protein 2 in rats with varicocele]. Beijing Da Xue Xue Bao Yi Xue Ban. 2016;48(4):579–583. Chinese.

27. Qian C, Xu Z, Chen L, Wang Y, Yao J. Long noncoding RNA LINCO1391 restrained gastric cancer aerobic glycolysis and tumorigenesis via targeting miR-12116/CMTM2 axis. J Cancer. 2020;11(21):6264–6276. doi:10.7150/jca.48365

26. Wu J, Li L, Wu S, Xu B. CMTM family proteins 1-8: roles in cancer biological processes and potential clinical value. Cancer Biol Med. 2020;17(3):528–542. doi:10.20892/jissn.2005-3941.2020.0032

25. Zhang XW, Dun YJ, Tang X, et al. [Expression of chemokine like factor-like myelin and lymphocyte and related proteins for vesicle trafficking and membrane link transmembrane domain-containing protein 2 in rats with varicocele]. Beijing Da Xue Xue Bao Yi Xue Ban. 2016;48(4):579–583. Chinese.

24. Zhang JW, Liu TF, Chen XH, et al. Validation of aspirin response-related transcripts in patients with coronary artery disease and preliminary investigation on CMTM5 function. Gene. 2017;624:56–65. doi:10.1016/j.gene.2017.04.041

23. Eichel MA, Gargareta VI, D’Este E, et al. CMTM6 expressed on the adaxonal Schwann cell surface restricts axonal diameters in peripheral nerve. Nat Commun. 2020;11(1):4514. doi:10.1038/s41467-020-18172-7

22. Kong LL, Wang ZY, Han N, et al. Neutralization of chemokine-like factor 1, a novel C-C chemokine, protects against focal cerebral ischemia by inhibiting neutrophil infiltration via MAPK pathways in rats. J Neuroinflammation. 2014;11:112. doi:10.1186/1742-2094-11-112

21. Iuchi T, Shibata K, Goto K, et al. CMTM expression in the adaxonal Schwann cell restricts axonal diameters in peripheral nerve. Nat Commun. 2020;11(1):4514. doi:10.1038/s41467-020-18172-7

20. Zhang JW, Liu TF, Chen XH, et al. Validation of aspirin response-related transcripts in patients with coronary artery disease and preliminary investigation on CMTM5 function. Gene. 2017;624:56–65. doi:10.1016/j.gene.2017.04.041

19. Arnold M, Laversanne M, Brown LM, Devesa SS, Bray F. Predicting the Future Burden of Esophageal Cancer by Histological Subtype: international Trends in Incidence up to 2030. Am J Gastroenterol. 2017;112(8):1247–1255. doi:10.1111/ajg.2017.112

18. Arnold M, Laversanne M, Brown LM, Devesa SS, Bray F. Predicting the Future Burden of Esophageal Cancer by Histological Subtype: international Trends in Incidence up to 2030. Am J Gastroenterol. 2017;112(8):1247–1255. doi:10.1111/ajg.2017.112

17. Sanikini H, Muller DC, Sophiea M, et al. Anthropometric and reproductive factors and risk of esophageal and gastric cancer. Int J Cancer. 2020;146(4):929–942. doi:10.1002/ijc.33286

16. Xie J, Yuan Y, Liu Z, et al. CMTM3 is frequently reduced in clear cell renal cell carcinoma and exhibits tumor suppressor activities. Clin Transl Oncol. 2014;16(4):402–409. doi:10.1007/s12094-013-1092-3

15. Hu F, Yuan W, Wang X, et al. CMTM3 is reduced in prostate cancer and inhibits migration, invasion and growth of LNCaP cells. Clin Transl Oncol. 2015;17(8):632–639. doi:10.1007/s12094-015-1288-9

14. Hu F, Yuan WQ, Wang XL, et al. [Knockdown of CMTM3 promotes migration and invasion of PC3 cell in vitro]. Beijing Da Xue Xue Bao Yi Xue Ban. 2016;48(1):594–597. Chinese.
54. Zhang H, Zhang J, Nan X, et al. CMTM3 inhibits cell growth and migration and predicts favorable survival in oral squamous cell carcinoma. *Tumour Biol. 2015;36*(10):7849–7858. doi:10.1007/s12709-015-2504-1

55. Abe M, Yamashita S, Mori Y, et al. High-risk oral leukoplakia is associated with aberrant promoter methylation of multiple genes. *BMC Cancer. 2016;16*:350. doi:10.1186/s12885-016-2371-5

56. Yuan W, Wei F, Ouyang H, et al. CMTM3 suppresses chordoma progress through EGFR/STAT3 regulated EMT and TP53 signaling pathway. *Cancer Cell Int. 2021;21*(1):10. doi:10.1186/s12953-021-02159-5

57. Bei C, Zhang Y, Wei R, et al. Clinical significance of CMTM4 expression in hepatocellular carcinoma. *Onco Targets Ther. 2017;10*:5439–5443. doi:10.2147/OTT.S149786

58. Zhou HQ, Li JH, Liu LW, Lou JM, Ren ZG. Increased CMTM4 mRNA expression predicts a poor prognosis in patients with hepatocellular carcinoma. *Hepatobiliary Pancreat Dis Int. 2019;16*(6):596–601. doi:10.1016/j.hbp.2020.06.004

59. Chui NN, Cheu JW, Yuen VW, et al. Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell-Mediated Antitumor Immunity Through PD-L1. *Hepatol Commun. 2021.* doi:10.1002/hep4.1682

60. Xue H, Li T, Wang P, et al. CMTM4 inhibits cell proliferation and migration via AKT, ERK1/2, and STAT3 pathway in colorectal cancer. *Acta Biochim Biophys Sin. 2019;51*(9):915–924. doi:10.1093/abbs/gmz084

61. Li T, Cheng Y, Wang P, et al. CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma. *J Exp Clin Cancer Res. 2015;34*:122. doi:10.1186/s13046-015-0236-4

62. Zhao W, Zhao F, Yang K, et al. An immunophenotyping of renal clear cell carcinoma with characteristics and a potential therapeutic target for patients insensitive to immune checkpoint blockade. *J Cell Biochem. 2019;120*(8):13330–13341. doi:10.1002/jcb.28607

63. Li H, Liu YT, Chen L, et al. CMTM4 regulates epithelial-mesenchymal transition and PD-L1 expression in head and neck squamous cell carcinoma. *Oncol Res Commun. 2021;21*(7):1248–1255. doi:10.1097/IGC.0b013e318259c31

64. Plate M, Li T, Wang Y, et al. Identification and characterization of CMTM4, a novel gene with inhibitory effects on HeLa cell growth through inducing G2/M phase accumulation. *Mol Cells. 2010;29*(4):355–361. doi:10.1007/s12059-010-0038-7

65. Xu G, Dang C. CMTM5 is downregulated and suppresses tumour growth in hepatocellular carcinoma through regulating PI3K-AKT signalling. *Cancer Cell Int. 2017;17*:113. doi:10.1186/s12935-017-0485-8

66. Wu J. CMTM5/7 are biomarkers and prognostic factors in human breast carcinoma. *Biochim Biophys Acta. 2011*(4):866–871. doi:10.1016/j.bbrc.2008.12.126

67. Zhou J, Lei J, Han Y, et al. Bioinformatics-Based Discovery of CKLF-Like MARVEL Transmembrane Member 5 as a Novel Biomarker for Breast Cancer. *Front Cell Dev Biol. 2020;7*:361. doi:10.3389/fcell.2019.00336

68. Chen Z, Cui N, Zhao JS, et al. Expressions of ZNF436, β-catenin, EGFR, and CMTM5 in breast cancer and their clinical significances. *Eur J Histochem. 2021;65*(5):3173. doi:10.4081/ejh.2021.3173

69. Yuan Y, Sheng Z, Liu Z, et al. CMTM5-v1 inhibits proliferation and migration by downregulating oncocgenic EGFR signaling in prostate cancer cells. *J Cancer. 2020;11*(3):3762–3770. doi:10.7150/jca.42314

70. Xiao Y, Yuan S, Yang S, et al. CMTM5 is reduced in prostate cancer and inhibits cancer cell growth in vitro and in vivo. *Clin Transl Oncol. 2015;17*(6):431–437. doi:10.1007/s12094-014-1253-z

71. Cai B, Xiao Y, Li Y, Zheng S. CMTM5 inhibits renal cancer cell growth through inducing cell-cycle arrest and apoptosis. *OncoLett. 2017;14*(2):1536–1542. doi:10.3892/ol.2017.6350

72. Shao L, Guo X, Plate M, et al. CMTM5-v1 induces apoptosis in cervical carcinoma cells. *Biochem Biophys Res Commun. 2009;379* (4):866–871. doi:10.1016/j.bbrc.2008.12.126

73. Li P, Liu K, Li L, et al. Reduced CMTM5 expression correlates with carcinogenesis in human epithelial ovarian cancer. *Int J Gynecol Cancer. 2011;21*(7):1248–1255. doi:10.1097/IGC.0b013e31822859c31

74. Guo X, Li T, Wang Y, et al. CMTM5 induces apoptosis of pancreatic cancer cells and has synergistic effects with TNF-alpha. *Biochem Biophys Res Commun. 2009;378*(1):139–142. doi:10.1016/j.bbrc.2009.06.148

75. Ma Y, Shi JF, Qiu HY, et al. [Pathophysiologic mechanism of CMTM5 low expression in multiple myeloma progression]. Zhonghua Xue Ye Xue Za Zhi. 2019;40*(4):58–62. doi:10.3760/cma.j.issn.0253-2727.2019.01.011 Chinese.

76. Niu JH, Bao L, Zhang Y, et al. [Abnormally lower expression of cmtm5 gene in bone marrow cells from patients with multiple myeloma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018;10*:362–367. Chinese.

77. Liu LL, Zhang SW, Chao X, et al. Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma. *Cancer Immunol Immunother. 2021;70*(2):417–429. doi:10.1007/s00262-020-02691-9

78. Zhu X, Qi G, Li C, et al. Expression and Clinical Significance of CMTM6 in Hepatocellular Carcinoma. *DNA Cell Biol. 2019;38*(2):193–197. doi:10.1089/dna.2018.4513

79. Yagawa K, Itoh S, Yoshizumi T, et al. CMTM6 Stabilizes PD-L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma. *Hepatol Commun. 2020;4*(5):334–348. doi:10.1002/hep4.1643

80. Huang X, Xiang L, Wang B, et al. CMTM6 promotes migration, invasion, and EMT by interacting with and stabilizing vimentin in hepatocellular carcinoma cells. *J Transl Med. 2021;19*(1):120. doi:10.1186/s12967-021-02787-5

81. Muranushi R, Araki K, Yokobori T, et al. High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence. *Cancer Sci. 2021;112*(8):3314–3322. doi:10.1111/cas.15004

82. Li X, Chen L, Gu C, Sun Q, Li J. CMTM4 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients. *PeerJ. 2020;8*:e9536. doi:10.7717/peerj.9536

83. Zhang C, Zhao S, Wang X. Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancer. *Cancer Cell Int. 2021;21* (1):78. doi:10.1186/s12935-020-01734-6

84. Peng QH, Wang CH, Chen HM, et al. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer. *J Immunother Cancer. 2021;9*(2):e001638. doi:10.1136/jitc-2020-001638

85. Wu X, Lan X, Hu W, et al. CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer. *Cancer Immunol Immunother. 2021;70*(11):3235–3248. doi:10.1007/s00262-021-02931-6

86. Shang X, Li J, Wang H, et al. CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma. *Int Immunopharmacol. 2020;88*:106864. doi:10.1016/j.intimp.2020.106864
87. Zuzagazgoitia J, Liu Y, Toki M, et al. Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer. J Thorac Oncol. 2019;14(12):2084–2096. doi:10.1016/j.jto.2019.09.014

88. Koh YW, Han JH, Haam S, Jung J, Lee HW. Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients. Oncology. 2019;8(10):e1629261. doi:10.1002/101629261

89. Wang H, Gao J, Zhang R, Li M, Peng Z, Wang H. Molecular and immune characteristics for lung adenocarcinoma patients with CMTM6 overexpression. Int Immunopharmacol. 2020;83:106478. doi:10.1016/j.intimp.2020.106478

90. Zheng Y, Wang C, Song A, et al. CMTM6 promotes cell proliferation and invasion in oral squamous cell carcinoma by interacting with NRPI. Am J Cancer Res. 2020;10(6):1691–1709.

91. Chen L, Yang QC, Li YC, et al. Targeting CMTM6 Suppresses Stem Cell-Like Properties and Enhances Antitumor Immunity in Head and Neck Squamous Cell Carcinoma. Cancer Immunol Res. 2020;8(2):179–191. doi:10.1158/2326-6066.CIR-19-0394

92. Zhang S, Yan Q, Wei S, et al. CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2021;132(2):202–209. doi:10.1016/j.ooos.2021.02.019

93. Mohapatra P, Shirivas O, Mohanty S, et al. CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO1- AKT/ GSK3β axis. JCI Insight. 2021;6(4):e143643. doi:10.1172/jci.insight.143643

94. Pang X, Wang SS, Zhang M, et al. OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway. Cancer Immunol Immunother. 2021. doi:10.1007/s00262-020-02741-2

95. Ishihara S, Iwasaki T, Kohashi K, et al. The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma. J Cancer Res Clin Oncol. 2021;147(7):2003–2011. doi:10.1007/s00432-021-03616-4

96. Huang ZM, Li PL, Yang P, et al. Overexpression of CMTM7 inhibits cell growth and migration in liver cancer. Kaohsiung J Med Sci. 2019;35(6):332–340. doi:10.1002/kjm.21208

97. Liu B, Su Y, Li T, et al. CMTM7 knockdown increases tumorigenicity of human non-small cell lung cancer cells and EGFR-AKT signaling by reducing Rab5 activation. Oncotarget. 2015;6(38):41092–41107. doi:10.18632/oncotarget.5732

98. Liu Q, Su Y, Jiang GC, et al. CMTM7 expression, a potential tumor suppressor, is associated with poor clinical outcome in human non-small cell lung cancer. Chin Med J. 2013;126(10):3006–3012.

99. Zhang W, Mendoza MC, Pei X, et al. Down-regulation of CMTM8 induces epithelial-to-mesenchymal transition-like changes via c-MET/ extracellular signal-regulated kinase (ERK) signaling. J Biol Chem. 2012;287(15):11850–11858. doi:10.1074/jbc.M111.258236

100. Yan M, Zhu Z, Qiao H, Zhang H, Xie W, Cai J. Downregulated CMTM6 Correlates with Poor Prognosis in Gastric Cancer Patients. DNA Cell Biol. 2021;40(6):791–797. doi:10.1089/dna.2021.10110

101. Gao D, Hu H, Wang Y, et al. CMTM8 inhibits the carcinogenesis and progression of bladder cancer. Oncol Rep. 2015;34(6):2853–2863. doi:10.3892/orc.2015.4310

102. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605–1617. doi:10.1056/NEJMra0910557

103. Hu H, Chen JW, Xu KX, et al. [Expressions of CMTM8 and E-cadherin in primary and metastatic clear cell renal cell carcinoma]. Beijing Da Xue Xue Bao Yi Xue Ban. 2013;45(4):537–541. Chinese.

104. Hatta M, Nagai H, Okino K, et al. Down-regulation of members of glycolipid-enriched membrane raft gene family, MAL and BENE, in cervical squamous cell cancers. J Obstet Gynaecol Res. 2004;30(1):53–58. doi:10.1111/j.1341-8076.2004.00156.x

105. Choi JH, Kim YB, Ahn JM, et al. Identification of genomic aberrations associated with lymph node metastasis in diffuse-type gastric cancer. Exp Mol Med. 2018;50(4):1–11. doi:10.1038/s12276-017-0099-6

106. Huang Y, Li F, Du Y. Effects of CKLFSF8 on expression of EGFR of BGC823 cell. J Zhongzhou Univ. 2006;41:617–619.

107. Zhao W, Xu Y, Xu J, et al. Subsets of myeloid-derived suppressor cells in hepatocellular carcinoma express chemokines and chemokine receptors differentially. Int Immunopharmacol. 2015;26(2):314–321. doi:10.1016/j.intimp.2015.04.010

108. Bei C, Tan C, Zhu X, Wang Z, Tan S. Association Between Polymorphisms in CMTM Family Genes and Hepatocellular Carcinoma in Guangxi of China. DNA Cell Biol. 2018;37(8):691–696. doi:10.1089/dna.2018.4274

109. Ma BB, Sung F, Tao Q, et al. The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines. Invest New Drugs. 2010;28(2):107–114. doi:10.1007/s10637-009-9219-7

110. Li T, Zhong J, Chen Y, et al. Expression of chemokine-like factor 1 is upregulated during T lymphocyte activation. Life Sci. 2006;79(6):519–524. doi:10.1016/j.lfs.2006.01.042

111. Yafune A, Kawai M, Itahashi M, et al. Global DNA methylation screening of liver in piperonyl butoxide-treated mice in a two-stage hepatocarcinogenesis model. Toxicol Lett. 2013;222(3):295–302. doi:10.1016/j.toxlet.2013.08.006

112. Kawai M, Saegusa Y, Kenmochi S, et al. Cytokeratin 8/18 is a useful immunohistochemical marker for hepatocellular proliferative lesions in mice. J Vet Med Sci. 2010;72(3):263–269. doi:10.1292/jvms.09-0329

113. Liu M, Guo H, Wang Q, et al. Pancreatic stellate cells derived exosomal miR-5703 promotes pancreatic cancer by downregulating CMTM4 and activating P38/Akt pathway. Cancer Lett. 2020;490:20–30. doi:10.1016/j.canlet

114. Shi W, Zhang C, Ning Z, et al. CMTM8 as an LPA1-associated partner mediates lysophosphatidic acid-induced pancreatic cancer metastasis. Am Transl Med. 2021;9(1):42. doi:10.21037/atm-20-1013

115. Li J, Chen C, Bi X, et al. DNA methylation of CMTM3, SSTR2, and MDFI genes in colorectal cancer. Oncol Rep. 2021;41:891–896. doi:10.3892/or.2021.11824

116. Li Z, Xie J, Wu J, et al. CMTM3 inhibits human testicular cancer cell growth through inducing cell-cycle arrest and apoptosis. PLoS One. 2014;9(2):e89865. doi:10.1371/journal.pone.0089865

117. Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583–589. doi:10.1038/s41586-021-03819-2

118. Varadi M, Anyango S, Deshpande M, et al. AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic Acids Res. 2022;50(D1):D439–D444. doi:10.1093/nar/gkab1061

119. Fishilevich S, Nudel R, Rappaport N, et al. Genome-wide integration of enhancers and target genes in GeneCards. Database (Oxford). 2017;2017:bax028. doi:10.1093/database/bax028
